Anesthesia Management

Introduction to Neuromuscular Blocking Agents

• Rocuronium causes complete paralysis of all voluntary muscles, including extraocular muscles, and does not provide sedation, analgesia, or amnesia, as noted by the American Academy of Pediatrics 1

Administration and Monitoring

• The American Academy of Pediatrics recommends ventilatory support and presence of personnel with airway management skills when administering rocuronium, with age-appropriate equipment for suctioning, oxygenation, intubation, and ventilation immediately available 1
• The European Society of Anaesthesiology and the American Society of Anesthesiologists recommend monitoring of neuromuscular blockade using train-of-four (TOF) stimulation of the adductor pollicis muscle, and electroencephalography (EEG) monitoring to detect seizure activity in patients who have received rocuronium 2

Dosage and Duration

• The standard intubating dose (0.6 mg/kg) of rocuronium has a duration of action of approximately 30-45 minutes, with a faster onset of action compared to vecuronium and atracurium, as recommended by the American Society of Anesthesiologists and the European Society of Anaesthesiology 1, 2
• Continuous infusion should be initiated at 10-12 mcg/kg/min after evidence of spontaneous recovery from the intubation dose, with bolus doses of 0.15 mg/kg administered when 25% recovery of T1 is observed, as recommended by the American Society of Anesthesiologists and the Anesthesia Society 2, 3

Special Considerations

• Patients with renal or hepatic failure may experience an extended duration of action of rocuronium, although the initial dose should not be modified, as noted by the European Society of Anaesthesiology 2
• Sugammadex is the preferred reversal agent for rocuronium-induced neuromuscular blockade, with dosing depending on blockade depth: 2.0 mg/kg for moderate blockade, 4.0 mg/kg for deep blockade, and 8.0 mg/kg for very deep blockade, as recommended by the American Society of Anesthesiologists and the European Society of Anaesthesiology 2
• Rocuronium is contraindicated in patients with known hypersensitivity to rocuronium or other neuromuscular blocking agents, and should only be used with adequate monitoring and facilities for intubation, ventilation, oxygen therapy, and immediate availability of an antagonist, as recommended by the American Society of Anesthesiologists 2
• Patients with specific conditions, such as renal or hepatic insufficiency, neuromuscular diseases, concomitant use of anticonvulsants, or chronic motor deficit, may require adjusted dosing of rocuronium and strict monitoring of neuromuscular blockade, as recommended by the European Society of Anaesthesiology and the American Society of Anesthesiologists 2
• Careful monitoring and dose adjustment are recommended to minimize the risk of residual neuromuscular blockade after surgery, as recommended by the Anesthesia Society 3

Comparison with Other Agents

2